J
Julieann Sludden
Researcher at Newcastle University
Publications - 19
Citations - 1114
Julieann Sludden is an academic researcher from Newcastle University. The author has contributed to research in topics: Pharmacokinetics & Cyclophosphamide. The author has an hindex of 11, co-authored 19 publications receiving 989 citations.
Papers
More filters
Journal ArticleDOI
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
Ruth Plummer,Richard H. Wilson,H. Calvert,Alan V. Boddy,MJ Griffin,Julieann Sludden,Michael J. Tilby,Martin Eatock,D.G. Pearson,Chris J. Ottley,Yasuhiro Matsumura,Kazunori Kataoka,T. Nishiya +12 more
TL;DR: The delayed and sustained release of cisplatin after i.v. administration contributes to the low toxicity of NC-6004 and the recommended dose was 90 mg m−2, although DLT was not defined as per protocol.
Journal ArticleDOI
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
Johanne Bray,Julieann Sludden,MJ Griffin,Michael Cole,Mark Verrill,David Jamieson,Alan V. Boddy +6 more
TL;DR: Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer and were associated with a worse outcome.
Journal ArticleDOI
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Yvette Drew,Jonathan A. Ledermann,Geoff Hall,Daniel Rea,R.M. Glasspool,Martin Highley,Gordon C Jayson,Julieann Sludden,James W. Murray,David Jamieson,Sarah Halford,Gary Acton,Zoe Backholer,Raffaella Mangano,Alan V. Boddy,Nicola J. Curtin,Ruth Plummer +16 more
TL;DR: In this article, intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer were investigated.
Journal ArticleDOI
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Alan V. Boddy,Elizabeth Ruth Plummer,R Todd,Julieann Sludden,MJ Griffin,Lisa Robson,Jim Cassidy,Donald Bissett,A Bernareggi,Mark Verrill,Alan Hilary Calvert +10 more
TL;DR: PPX is a water-soluble paclitaxel-polymer conjugate with a prolonged half-life and limited volume of distribution and dose-limiting toxicities were neutropenia and neuropathy.
Journal ArticleDOI
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Ruth Plummer,Laura Vidal,MJ Griffin,Mark Lesley,Johann S. de Bono,Sally A. Coulthard,Julieann Sludden,Lillian L. Siu,Eric Chen,Amit M. Oza,Gregory K. Reid,A. Robert McLeod,Jeffrey M. Besterman,C. Lee,Ian Judson,Hilary Calvert,Alan V. Boddy +16 more
TL;DR: MG98 was well tolerated with mild fatigue and myalgia, dose-limiting toxicity was asymptomatic transaminitis, and the maximum tolerated dose was 200 mg/m2/d; proof of mechanism was observed and measurement of DNMT1 expression in peripheral blood mononuclear cells may be useful in future phase II development.